

anti-HBs in Rhesus monkeys (RTS,S)




Fig. 1

## ANTIGEN HbsAg

GROUP	FORMULATION	IgG1			IgG2a			IgG2b		
		PostII5	PostII7	PostII15	PostII5	PostII7	PostII15	PostII5	PostII7	PostII15
1	SB62	275	3861	4171	44	479	1134	81	700	704
2	QS21 MPL	33	2533	2146	176	5301	5464	138	2235	1160
3	QS21 MPL SB62	130	1248	1774	498	8551	15806	371	5107	3606
4	AL(OH)3 MPL	187	1138	2501	129	1832	4059	249	2621	1441
5	AL(OH)3	130	936	1562	13	128	658	265	192	951
6	plain	6	426	490	6	90	87	5	226	183
7	neg Controls	5	5	5	5	5	5	5	5	5

Fig. 2a

3/7




Fig. 2b

anti HbsAg IgG2a pool




Fig. 2c

5/7

anti HbsAg IgG2b pool






Fig. 2d

Anti-OspA Abs titers (Igt) after immunization of Balb/C mice  
with diff rent formulations of Lipoprotein OspA





**Fig. 3a**



**Fig. 3b**

7 / 7

Anti-OspA Abs titers (IgG2a) after immunization of Balb/C mice  
with different formulations of Lipoprotein OspA

**Fig. 4a****Fig. 4b**